Northwell Health is a not-for-profit, integrated health system based in New Hyde Park, New York, and the largest healthcare provider in New York State. It operates a network of hospitals and outpatient facilities and is affiliated with the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Through its research arm, the Feinstein Institutes for Medical Research, Northwell conducts basic, translational, and clinical research and runs clinical trials across areas such as immunology, oncology, neurology, and infectious diseases. The organization collaborates with academic, biopharma, and medical device partners to advance therapies, diagnostics, and care delivery, providing infrastructure for regulatory-compliant studies and data-driven evidence generation.
None yet. When a new project in the record names Northwell as owner, partner or investor, it shows here.
Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
Gazyva shows significant improvement in SLE symptoms, achieving a 76.7% response rate and doubling remission rates in a Phase III trial, as published in NEJM.
Nipocalimab, an investigational therapy, aims to address unmet needs in lupus by reducing harmful IgG while preserving immune function, following positive Phase 2b results.
